A therosclerotic vascular disease is a chronic inflammation of the arterial vessel wall causing a severe socioeconomic burden in western socities. 1 A commonly used interventional technique to widen arteries narrowed by atherosclerotic lesions is angioplasty. In turn, this intervention induces severe arterial damage, possibly leading to the recurrence of stenosis, termed restenosis. Although the incidence of restenosis has declined because of the use of drug-eluting stents and antiplatelet therapy, further optimization of angioplasty remains an important topic.
Results
To identify the source of AnxA1, we stained healthy and injured carotid arteries from Apoe −/− mice fed a high-fat diet, for AnxA1 ( Figure I in the online-only Data Supplement), along with specific markers for endothelial cells (CD31), smooth muscle cells (α-smooth muscle actin), and macrophages (Mac2). In either case, AnxA1 was found to primarily colocalize with endothelial cells and macrophages ( To study a potential role of AnxA1 during arterial injury, we correlated neointima sizes in Apoe −/− mice 4 weeks after wire 
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injury with AnxA1 plasma levels measured by ELISA ( Figure 1C ) or the degree of lesional AnxA1 expression ( Figure 1D ). In both analyses, a negative correlation was perceived suggestive of a protective effect of AnxA1 in healing after injury.
To establish a causal contribution of AnxA1 in arterial healing, Apoe −/− and Apoe −/− Anxa1 −/− mice were subjected to wire injury while fed a high-cholesterol diet. No significant differences were observed in myeloid cell counts in the blood, bone marrow, and spleen (Table I in 
Anxa1
−/− mice showed a marked increase in neointima size, corroborating a protective effect of AnxA1 (Figure 2A) . To reveal the cell type that is responsible for the aggravation of neointima growth, the cellular composition of the neointima was characterized. No changes were observed in the number of smooth muscle cells present in the neointima ( Figure 2B ). However, in line with the predominant expression of AnxA1 in macrophages, we evidenced an expansion of these cells in neointimal lesions obtained from AnxA1-deficient mice (Figure 2C and 2D ; Figure VI in the online-only Data Supplement), which can possibly be attributed to a larger fraction of proliferating macrophages in these mice ( Figure 2E ). In addition, more M-CSF (macrophage colony-stimulating factor) staining was found in neointima sections from Apoe 
Discussion
In the present study, we examined the role of AnxA1 in healing after arterial injury. We witnessed a prominent expression of AnxA1 in endothelial cells and macrophages residing in the neointima. Lesional AnxA1 and plasma AnxA1 levels negatively correlated with neointima area, suggestive of a reparative role of AnxA1. In AnxA1-null mice, neointima development was mainly aggravated by the accumulation of proliferating macrophages in the injured tissue.
Inflammatory macrophages are histologically identified within neoatherosclerosis in human coronary implants and stents. 10 Arterial macrophage accumulation is controlled by different mechanisms, including apoptosis, recruitment, and proliferation. 11 In previous work, it has been shown that AnxA1 and its N-terminal fragment Ac2-26 counteract chemokine-induced integrin activation by inhibition of Rap1 activation in monocytes and, therefore, restrains adhesion to large arteries. 5 Consequently, enhanced recruitment of monocytes in AnxA1-deficient mice may contribute to the phenotype observed in the present study. Moreover, macrophage proliferation instigated by modified lipids and proinflammatory meditators in atherosclerotic lesions is a denominator of arterial macrophage accumulation. 12 Herein, we found an increase in the number of proliferating macrophages in AnxA1-null mice, suggesting that AnxA1 acts as negative regulator of macrophage proliferation. In line with those findings, an elevated M-CSF staining in the neointima of AnxA1-deficient mice was found, as well as an inhibitory effect of recombinant AnxA1 on the expression and release of M-CSF by macrophages in vitro. By which mechanism AnxA1 controls M-CSF production in macrophages and if this is of relevance also during advanced stages of atherosclerosis remain to be defined. Taken together, the phenotype observed in our model likely originates from a combination of augmented monocyte recruitment and the increased ability of arterial macrophages to proliferate in the absence of AnxA1 (Graphic Abstract in the online-only Data Supplement).
Therapeutic intervention with AnxA1 or its bioactive peptide Ac2-26 have proven to be beneficial in mouse models of arterial vascular disease. 5, 13 Of note, it has been demonstrated that arterial-specific nanodelivery of Ac2-26 could be a promising tool to prevent atheroprogression, a strategy that may also be applicable to treatment of angioplasty-related side effects. 14 In line with previously successfully used FPR2 ligands, 3 stents coated with AnxA1 protein could potentially be suitable to prevent lumen loss and inflammation after arterial injury.
Sources of Funding
The study was supported by the DFG (Deutsche Forschungsgemeinschaft; SFB914 B08, SFB1123 A06 & B05, SO876/6-1, SO876/11-1), the NWO (Nederlandse Organisatie voor Wetenschappelijk Onderzoek; VIDI project 91712303), and the LMU (Ludwig-MaximiliansUniversität) excellent program.
